Why I Decided to Return Apple Vision Pro After a Week

Why I Decided to Return Apple Vision Pro After a Week

I fully expected it, but it has the limitations of the hydroponic headset form factor itself and the basic problems of a typical first-generation product. It's heavy, uncomfortable, has no dedicated app to use, lacks immersive content, and is even expensive. The high price makes sense through the magical experience of using intensive technology, but when I spent a week intensively, there was nothing more I could do. The best thing to do was watch movies on Disney apps or watch YouTube and Netflix on Safari browsers. I thought about using it continuously because it wasn't as dizzy as I was concerned, but I thought it would be better to wait for the second-generation product.

And most of all, I felt my eyes get a little weird. After using Vision Pro for hours every day to shoot videos, it seemed to be subtly floating even when I looked at the handwriting of a smartphone or a general monitor. It's a brain feature, but it seems that the eye and brain are adapted due to the nature of a 3D device that synthesizes two scenes through two lances. Of course, I took off the headset and returned to normal after enough time, and it is certain to have a negative effect on my eyes and brain.

The utilization is maximized in cafes, libraries, or cars outside the house where 4K large monitors or projectors are not available. All of the spaces I usually use have large monitors and projectors, are unnecessary while driving, and I have time to spare when I wait for my wife, but that doesn't happen very often and the waiting time is too short to wear. No matter how much I try to carry it around and use it every time I go from place to place, it was so inconvenient to use it as a MacBook, iPad, or iPhone.

Especially these days, MacBooks and pads are heavy, so I carry only the iPhone and AirPods Pro 2. You need enough time to use it to watch immersive content, but it was unnecessary because you could spend time outside and you were often with your wife wherever you went. In a word, there were few situations where you could take out and use an interesting but uncomfortable Vision Pro. Of course, I'm sorry to return expensive products after using them as much as I can, but I'm glad that it's convenient to return them as I live in the United States.

Finally, since it was released on February 2, the success or failure of the return articles will be confirmed by the flood of return articles after February 16, two weeks after the free return is possible. I have never returned Apple products in my life, but I personally think it is a disaster because it is difficult to wear them for more than 30 minutes. Or, it must have been released as a groundwork for creating an ecosystem by informing developers of the possibility of the device or as a market test through early adopters. McKinsey's Korea Report, published in December last year, was published in December

1. Regardless of the good or bad content, this attempt to present a strategy for the entire Korean industry in a 60-page report is worth learning.

2. There are more places that produce such comprehensive reports in domestic institutions, and regardless of the quality, it is admirable.

3. Our lab also has to publish a report like <STEPI Solution on Technological Innovation in Korea>....

Wondering if there is any review or criticism of the p.s. McKinsey report

<Additional> If you look at the bio...
p.22 "In the bio industry, not only global leaders but also bio venture companies are committed to developing original technologies for 3rd generation new drugs (CGT) such as cell/gene therapy, a new growth area."
-> Cell gene therapy seems to be the key keyword. It's an important area, but it's hard to say that we should focus on it. What will happen to ADC that's emerging these days...

p.24 The biopharmaceutical industry.
Accordingly, it is necessary to increase venture capital investment in bio ventures and create an environment in which bio ventures can operate successfully. For example, measures should be devised to expand the procurement of new capital for bio ventures with technological prowess but lack of funding and to facilitate the attraction of overseas talent. In addition, the establishment of new drug development processes and initial regulations related to approval, which are not systematic compared to leading countries with a lot of experience in developing original new drugs, should be carried out. In addition, it is necessary to establish a cooperative relationship with bio ventures by appealing for the mass production capacity and operational efficiency that Korea's leading CMO (consignment production and development company) can provide. As mentioned earlier, most of the 3rd generation drug developers are small and medium-sized enterprises that do not have production facilities. They are highly dependent on CMO outsourcing due to the high difficulty, complexity, and reduction of development risk of production processes and logistics. Therefore, it can be seen that the success of 3rd generation drug developers is highly related to close cooperation with CMO. In Korea, outstanding CMOs based on large corporations are growing rapidly, but companies with second-generation drug production experience should quickly secure the 3rd generation drug production performance. To this end, it is also necessary to consider establishing production bases overseas, where many third-generation bio ventures are located.

-> Where the largest number of votes are written by those who are not familiar with the biopharmaceutical field. What does "systematic new drug development process" mean? The strategy that binds new drug development venture companies and CMOs is the most out of touch with reality. It is common for new drug development venture companies not to consider production, and the dominant business model is that they license out in the middle. "We are highly dependent on CDMO outsourcing for reasons such as high difficulty in production processes and logistics, and reduced risk of complexity development"??? It seems that an MBA-turned-consultant who did not understand this industry wrote the report without knowing the most common business model of new drug development venture companies. If you Google it, this is a strategy that can be easily identified... Above all, the biggest problem is not seeing my report or presentation materials... ?

http://www.mckinsey.com/kr/~/media/mckinsey/locations/asia/korea/our%20insights/koreas%20next%20s%20curve%20a%20new%20economic%20growth%20model%20for%202040/koreas-next-s-curve-a-new-economic-growth-model-for-2040-ko.pdf